Trials / Unknown
UnknownNCT03129724
Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- University Hospital, Strasbourg, France · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Describe in patients with metastatic kidney cancer treatment modalities with the type sequences: TKI - mTORi - Axitinib or VEGF mAb - mTORi - Axitinib.
Conditions
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2017-07-01
- Completion
- 2017-07-01
- First posted
- 2017-04-26
- Last updated
- 2017-04-26
Source: ClinicalTrials.gov record NCT03129724. Inclusion in this directory is not an endorsement.